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Assessing the treatment effect from
multiple trials in idiopathic pulmonary
fibrosis
Luca Richeldi
ABSTRACT: The magnitude of treatment effect can be assessed by a number of methods. One
method of collectively analysing data is that used by the Cochrane Collaboration. Their
systematic reviews identify, analyse and present research-based evidence in an accessible
format. These reviews may contain meta-analyses combining data from multiple studies to
provide robust evaluations of overall treatment effects.
In 2003, Cochrane reviews of data for treatment with corticosteroids in idiopathic pulmonary
fibrosis (IPF) found no evidence supporting their use; similarly, reviews of immunomodulatory
agents found very little evidence to support their use.
A recent update of these Cochrane reviews failed to identify any evidence supporting the use of
corticosteroids in IPF; however, a review of non-steroid agents in the treatment of IPF identified 15
clinical trials suitable for analysis. Two trials of interferon-c-1b were combined, and no treatment
effect was observed in terms of survival. Two Japanese trials of treatment with pirfenidone were
combined, and a positive effect of pirfenidone on pulmonary function decline was observed. Meta-
analysis of three phase III studies suggested that pirfenidone significantly increased progression-
free survival by 30%.
The findings of this systematic review, although not presenting new original data, together with
an acceptable safety profile, suggest that pirfenidone may have a role in IPF treatment.
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U
ntil approximately 40 yrs ago, clinical
practice was not based on evidence de-
rived from the combined results of rando-
mised clinical trials. A seminal book published in
1972 by the British professor Archibald Cochrane
[1] highlighted this fact, and stressed the impor-
tance of using evidence from randomised con-
trolled trials (RCTs) to guide daily clinical
practice. He suggested that RCTs were likely to
provide more highly reliable information than
other potential sources of evidence. This book
became the basis for the way in which the UK
National Health Service provided treatment.
Clinical practice today takes into account the
results published from RCTs, as well as recom-
mendations issued by expert committees; how-
ever, the main issue in obtaining accurate treat-
ment guidelines is how to combine data from
various clinical trials in order to assess the real
benefits of any given therapy.
HOW TO ACCURATELY ASSESS THE
EFFECT OF A THERAPY
Combining data from different clinical trials for
one given therapy or disease area can often be
difficult, even when trials are similar in design.
Some trials may not be large enough to provide
significant data, and others may have non-
comparable end-points. One approach is to pool
data from similarly designed studies. For exam-
ple, two phase III trials of pirfenidone in patients
with idiopathic pulmonary fibrosis (IPF) [2] were
similarly designed in order to enable pooling of
data. Analysis of pooled data from both trials
was conducted to derive precise estimates of
the magnitude of the treatment effect [2]. The
number of clinical trials carried out in IPF is now
accumulating rapidly, and a decision should
soon be made on the recommended treatment
strategy based on evidence emerging from multi-
ple trials. However, the question remaining is:
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what is the ideal method to assess the overall effect of a
therapy based on multiple different trials?
THE COCHRANE COLLABORATION
Following the publication in 1972 of the book Effectiveness and
Efficiency by COCHRANE [1], a non-profit network known as the
Cochrane Collaboration was established with the aim of
analysing existing data on various treatment effects. The
Cochrane Collaboration publishes systematic reviews, which
identify, analyse and present research-based evidence in an
accessible format [3]. The Cochrane reviews differ from classical
scientific reviews (also known as non-systematic reviews) as
they do not simply reflect the opinions of the authors; they aim to
reduce bias possibly generated by individual opinions or
practices. Cochrane reviews are based on a systematic analysis
of all published data for a given treatment, which is based on a
pre-defined analysis and may contain a meta-analysis. Meta-
analysis is a statistical approach to aggregating data from re-
levant clinical trials and, thus, providing more precise estimates
of the effects of a given treatment. There are pre-defined criteria
for the inclusion of trials in a Cochrane meta-analysis. Meta-
analyses are typically conducted on a study end-point and
graphically depicted as ‘‘forest plots’’ [4]. The forest plot shows
the effect of different studies on a given end-point. The vertical
line in the middle of the forest plot represents the line of ‘‘no
effect’’. The areas to either side of the no-effect line are
representative of the individual studies being either favourable
to the treatment or to placebo. Each study is evaluated and
represented on the plot by a square (which shows the effect of
the individual study, with the square varying in size to account
for the weight any one study has on the overall analysis, i.e. the
larger the square the more weight the study has) and line
(representing the 95% confidence interval of a study). The
diamond at the bottom of the plot represents the pooled result
(overall effect) of all studies, with the outer edges representing
the 95% confidence intervals.
A classic example of the importance of meta-analysis is the
study published in 1992 by ANTMAN et al. [5] on the effects of
oral b-blockers for the secondary prevention of mortality in
patients surviving a myocardial infarction (fig. 1). This study
showed that a number of trials on this specific topic were
unnecessarily carried out, because a meta-analysis of the pre-
vious studies wasn’t performed. Such an analysis, if timely,
would have identified the use of b-blockers as the standard of
care for heart failure patients, thus avoiding the performance
of many other placebo-controlled trials.
PHARMACOLOGICAL TREATMENT OF IPF
In 2000, the American Thoracic Society and European Respi-
ratory Society published an international consensus statement
with guidelines for the diagnosis and treatment of IPF [6]. The
guidelines recommended that until adequate studies were
conducted to define the best treatment for patients with IPF,
they should be treated with a combined therapy of corticoster-
oids and an immunosuppressive agent (e.g. azathioprine or
cyclophosphamide). In 2003, a Cochrane review was published
on the use of corticosteroids in IPF [7]. This review highlighted
that there were no placebo-controlled clinical trials analysing
the efficacy of corticosteroid therapy in IPF patients and,
therefore, there was no existing evidence to support the efficacy
of corticosteroids alone in the treatment of IPF.
Moreover, DAVIES et al. [8] published a Cochrane review in
2003 on the use of immunomodulatory agents in IPF. The
authors found four randomised controlled clinical studies
suitable for a meta-analysis [9–12]; however, these four small
studies used four different immunosuppressive agents (cyclo-
phosphamide, azathioprine, colchicine and interferon (IFN)-c-
1b) and thus it was not actually possible to conduct a meta-
analysis. The authors concluded that there was little evidence
to justify the routine use of any immunosuppressive agent (or
in fact any non-corticosteroid agent) in the management of IPF,
either as sole therapy or as steroid-sparing agents.
In 2010, the Cochrane meta-analysis on the use of cortico-
steroids for IPF was updated [13]. However, 7 yrs after the
publication of the first Cochrane review on the use of
corticosteroids in IPF, there was still no evidence supporting
the routine use of corticosteroids alone in the management of
IPF [13]. Since 2003, no placebo-controlled trials of cortico-
steroids in IPF have been undertaken, probably due to the fact
that there was no previous clear evidence to show that they
were or were not an effective treatment option. Therefore,
clinicians were left with continued uncertainty over the use of
these agents in IPF.
In 2010, a systematic search was conducted to identify RCTs
carried out using non-steroid agents for the treatment of IPF. This
then became the subject of an updated Cochrane review [14].
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FIGURE 1. Effects of oral b-blockers for a secondary prevention of mortality in
patients surviving a myocardial infarction Individual randomised clinical trials and
overall meta-analysis result. z5 -4.47, p,0.00001. Reproduced from [5] with
permission from the publisher.
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The search for relevant clinical trials involved the use of various
trial registries and databases, as well as direct contact with
pharmaceutical companies and researchers in this field. The end-
points of trials identified as potentially suitable for inclusion
were reviewed, and their methodological quality assessed. This
systematic search found that up to 2003, four clinical studies
were eligible for a meta-analysis, while in 2010, 13 studies could
be included. Contact with pharmaceutical companies and
researchers led to identification of two further clinical trials
which were suitable for meta-analyses (fig. 2) and were to be
published soon after. The analysis of end-points and quality of
the methodology of these 15 trials reduced the number of eligible
trials to seven (fig. 3): only the anti-fibrotic agents IFN-c-1b and
pirfenidone were evaluated in more than one trial and, as such,
were potentially eligible for two meta-analyses.
Combining the data from the two RCTs on IFN-c-1b [15, 16] in
a meta-analysis of the clinical end-point of overall survival
(both trials reported hazard ratio estimates) showed that there
were no statistically significant differences in mortality
between IFN-c-1b and placebo (fig. 4). Interestingly, the larger
of the two trials, published by KING et al. [15], was negative for
efficacy in terms of the overall survival end-point, whereas the
smaller trial almost demonstrated statistical significance [16].
Meta-analyses were performed to determine the treatment
effect of pirfenidone. The two Japanese clinical trials [18] could
be combined in an analysis on the end-point of absolute
change in vital capacity (fig. 5) [16]. Statistically significant
differences were observed in terms of decline in vital capacity
between the pirfenidone and placebo groups. This meta-
analysis confirmed the beneficial effect of pirfenidone on the
change of vital capacity compared to baseline. The CAPACITY
1 and 2 studies [2] measured the end-point of change in per
cent predicted forced vital capacity (FVC), with the results
being analysed using a rank analysis, and thus the hetero-
geneity of these studies did not allow for their inclusion in the
same meta-analysis.
For the combined end-point of progression-free survival (PFS),
progression being defined as either death or 10% decrease in
FVC, data from the CAPACITY 1 and 2 studies and the
Japanese study published by TANIGUCHI et al. [18] could be
combined in a meta-analysis (fig. 6). The CAPACITY 1 and 2
studies reported the hazard ratio (HR) estimate and 95%
confidence intervals (CIs). The Japanese study did not report
the HR; however, this was estimated indirectly using the
information from the survival curves reported by the authors.
In CAPACITY 2 and the study by TANIGUCHI et al. [18], similar
and significant differences were observed in PFS between the
pirfenidone and placebo arms. There was, however, a non-
significant effect in terms of PFS observed in CAPACITY 1. The
overall result of this meta-analysis suggests that treatment with
pirfenidone reduced the risk of disease progression by 30%
(HR 0.70, 95% CI 0.56–0.88).
It is noteworthy that a recent publication by VANCHERI et al. [24]
observed that IPF has similarities and links to the biology of
neoplastic disorders. In light of the biological and prognostic
similarities between IPF and lung cancer, there may be a
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FIGURE 2. Two systematic searches for randomised clinical trials of non-steroid agents in idiopathic pulmonary fibrosis (IPF) up to 2003 and up to 2010. IFN: interferon.
7 randomised clinical trials eligible for two 
potential meta-analyses
CAPACITY 1 [2]: pirfenidone
CAPACITY 2 [2]: pirfenidone
AZUMA [17]: pirfenidone
TANIGUCHI [18]: pirfenidone
ZIESCHE [12]: IFN-γ-1b
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FIGURE 3. Randomised clinical trials of non-steroid agents in idiopathic
pulmonary fibrosis eligible for meta-analyses. IFN: interferon.
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rationale for adopting PFS as a primary end-point in
therapeutic clinical trials in IPF, especially as many commonly
used drugs for the treatment of nonsmall cell lung cancer were
approved on the basis of an effect on PFS [25–27]. Indeed, the
magnitude of the treatment effect of pirfenidone on PFS in the
previously referenced meta-analysis was generally consistent
with the magnitude of effect of adjuvant platinum-based
chemotherapy in a meta-analysis of 10 RCTs in patients with
nonsmall cell lung cancer (HR 0.87, 95% CI 0.79–0.94) [28].
CONCLUSIONS
With the number of good-quality randomised controlled clinical
trials in IPF increasing, systematic reviews containing meta-
analyses recently became feasible. The advantages and limita-
tions of meta-analysis do, however, need to be appreciated. For
example, it is not always possible to combine the results from all
trials that have investigated the treatment of a particular disease
if they differ in terms of end-points and analysis. Also, it is im-
portant to note that the results of meta-analyses do not cons-
titute new clinical data, since they are based on the combination
of previously performed studies: as such, the results of meta-
analyses should be considered carefully before being directly
applied to clinical practice. Nonetheless, systematic reviews are
helpful to identify previously unrecognised missing gaps or
to confirm results from smaller studies. For example, meta-
analysis of the efficacy of corticosteroids in IPF has shown that
there is no evidence to support their use. In fact, the most
recently published 2011 American Thoracic Society/European
Respiratory Society/Japanese Respiratory Society/Latin-
American Thoracic Society guidelines for the diagnosis and
management of IPF gave a strong recommendation against
corticosteroid monotherapy [29]. Indeed, the available com-
bined data point to a role for pirfenidone in treating IPF
patients. Bearing in mind that the ultimate goal is successfully
treating IPF, evidence from systematic reviews should play a
role in designing future clinical trials and in fostering
international networking, which is key to understanding and
improving the treatment of IPF.
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